Skip to main content
Premium Trial:

Request an Annual Quote

NIH Adds 22 New Partner Centers to National Children’s Study; $69M Flowing Already

NEW YORK (GenomeWeb News) - The National Institute of Child Health and Human Development this week disclosed 22 centers and universities that are participating in the National Children's Study — a massive longitudinal effort that will gather and analyze genetic and environmental data from 100,000 participants from before birth to the age of 21.
 
The NCS will use a $69 million appropriation from Congress to jump-start the study, which first plans to recruit 100,000 pregnant and soon-to-be-pregnant women throughout the country.
 
The study will start with an ambitious door-knocking campaign, Thomas McLaughlin, a professor of pediatrics at the University of Massachusetts and a principal investigator for the NCS at the UMass Medical School at Worcester, told GenomeWeb Daily News.
 
McLaughlin said the UMass Medical School will receive $16 million over five years for its work in the study and that it expects to hire between 80 and 100 new employees.
 
The study is a collaboration between the NICHD, the National Institute of Environmental Health Sciences, the Centers for Disease Control and Prevention, and the US Environmental Protection Agency.
 
McLaughlin said that genetics and genomics studies will make up as much as 50 percent of the project and that he expects RNAi studies to be a point of focus at UMass.
 
NIH Director Elias Zerhouni said the NCS is "poised to identify the early antecedents of a broad array of diseases that affect both children and adults."
 
NICHD has not yet made publicly available the full amounts of funding each of the 22 NCS research partners are to receive.
 
The institutes receiving funds include: Brown University, Children's Hospital of Philadelphia; Emory University; Johns Hopkins University; Michigan State University; Mount Sinai School of Medicine; Northwestern University; St. Louis University: University of California, Davis; University of California, Irvine; University of Hawaii at Manoa; University of Massachusetts, University of Minnesota; The University of Mississippi; University of New Mexico; The University of North Carolina at Chapel Hill; University of Pittsburgh; The University of Texas Health Science Center at San Antonio; The University of Utah; University of California, Los Angeles; University of Washington; and Yale University.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.